PittsburghV1, Main, Merge, bibRecord, 005629

Integration of molecular targeted therapy with radiation in head and neck cancer

Identifieur interne : 005629 ( Main/Merge ); précédent : 005628; suivant : 005630

Integration of molecular targeted therapy with radiation in head and neck cancer

Auteurs : YU DU [États-Unis, République populaire de Chine] ; Noah D. Peyser [États-Unis] ; Jennifer R. Grandis [États-Unis]

Source :

Pharmacology & therapeutics : (Oxford) [ 0163-7258 ] ; 2014.

RBID : Pascal:14-0117820

Descripteurs français

Pascal (Inist)
- Intégration moléculaire, Traitement, Thérapeutique ciblée, Radiothérapie, Cancer de la tête et du cou, Carcinome épidermoïde de la tête et du cou, Essai préclinique, Modèle, Essai clinique, Homme, Récepteur facteur croissance épiderme, Récepteur facteur croissance.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Clinical trial, Epidermal growth factor receptor, Growth factor receptor, Head and neck cancer, Head and neck squamous cell carcinoma, Human, Models, Molecular integration, Preclinical trial, Radiotherapy, Targeted therapy, Treatment.

Abstract

Approximately 600,000 new cases of head and neck cancer arise worldwide each year. Of these, a large majority are head and neck squamous cell carcinomas (HNSCC). Conventional treatments, including surgical excision followed by radiation and/or chemoradiotherapy have limited efficacy and are associated with substantial toxicity. To date, key targets for molecular targeted therapy in HNSCC are epidermal growth factor receptors and angiogenesis-related factors. Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR) and it is the only targeted therapy approved by the United States Food and Drug Administration for the treatment of HNSCC. Cetuximab in combination with radiotherapy represents a standard approach for newly diagnosed patients who are unable to tolerate platinum chemotherapy. Despite efficacy in preclinical HNSCC models, cetuximab is only effective in a subset of HNSCC patients, most likely due to the high heterogeneity of this cancer. Additional targets under active investigation include the PI3K/Akt pathway, the Ras-MAPK-ERK pathway and the JAK/STAT pathway, among others. Combining molecular targeted therapies and radiation may allow for deintensification of radiotherapy thereby reducing radiation toxicities and improving treatment outcomes. Here we review the preclinical and clinical data in support of treatment strategies that combined targeted therapy with radiation in HNSCC.

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000B94
to stream PascalFrancis, to step Curation: 003A28
to stream PascalFrancis, to step Checkpoint: 000706

Links to Exploration step

Pascal:14-0117820

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Integration of molecular targeted therapy with radiation in head and neck cancer</title>
<author><name sortKey="Yu Du" sort="Yu Du" uniqKey="Yu Du" last="Yu Du">YU DU</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Otolaryngology, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, PA 15213</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pittsburgh, PA 15213</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>School of Medicine, Tsinghua University</s1>
<s2>Beijing 100084</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Peyser, Noah D" sort="Peyser, Noah D" uniqKey="Peyser N" first="Noah D." last="Peyser">Noah D. Peyser</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Otolaryngology, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, PA 15213</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pittsburgh, PA 15213</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, PA 15213</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pittsburgh, PA 15213</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Grandis, Jennifer R" sort="Grandis, Jennifer R" uniqKey="Grandis J" first="Jennifer R." last="Grandis">Jennifer R. Grandis</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Otolaryngology, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, PA 15213</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pittsburgh, PA 15213</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, PA 15213</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pittsburgh, PA 15213</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0117820</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0117820 INIST</idno>
<idno type="RBID">Pascal:14-0117820</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B94</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003A28</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000706</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000706</idno>
<idno type="wicri:doubleKey">0163-7258:2014:Yu Du:integration:of:molecular</idno>
<idno type="wicri:Area/Main/Merge">005629</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Integration of molecular targeted therapy with radiation in head and neck cancer</title>
<author><name sortKey="Yu Du" sort="Yu Du" uniqKey="Yu Du" last="Yu Du">YU DU</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Otolaryngology, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, PA 15213</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pittsburgh, PA 15213</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>School of Medicine, Tsinghua University</s1>
<s2>Beijing 100084</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Peyser, Noah D" sort="Peyser, Noah D" uniqKey="Peyser N" first="Noah D." last="Peyser">Noah D. Peyser</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Otolaryngology, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, PA 15213</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pittsburgh, PA 15213</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, PA 15213</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pittsburgh, PA 15213</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Grandis, Jennifer R" sort="Grandis, Jennifer R" uniqKey="Grandis J" first="Jennifer R." last="Grandis">Jennifer R. Grandis</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Otolaryngology, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, PA 15213</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pittsburgh, PA 15213</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, PA 15213</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pittsburgh, PA 15213</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Pharmacology & therapeutics : (Oxford)</title>
<title level="j" type="abbreviated">Pharmacol. ther. : (Oxf.)</title>
<idno type="ISSN">0163-7258</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Pharmacology & therapeutics : (Oxford)</title>
<title level="j" type="abbreviated">Pharmacol. ther. : (Oxf.)</title>
<idno type="ISSN">0163-7258</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical trial</term>
<term>Epidermal growth factor receptor</term>
<term>Growth factor receptor</term>
<term>Head and neck cancer</term>
<term>Head and neck squamous cell carcinoma</term>
<term>Human</term>
<term>Models</term>
<term>Molecular integration</term>
<term>Preclinical trial</term>
<term>Radiotherapy</term>
<term>Targeted therapy</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Intégration moléculaire</term>
<term>Traitement</term>
<term>Thérapeutique ciblée</term>
<term>Radiothérapie</term>
<term>Cancer de la tête et du cou</term>
<term>Carcinome épidermoïde de la tête et du cou</term>
<term>Essai préclinique</term>
<term>Modèle</term>
<term>Essai clinique</term>
<term>Homme</term>
<term>Récepteur facteur croissance épiderme</term>
<term>Récepteur facteur croissance</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Approximately 600,000 new cases of head and neck cancer arise worldwide each year. Of these, a large majority are head and neck squamous cell carcinomas (HNSCC). Conventional treatments, including surgical excision followed by radiation and/or chemoradiotherapy have limited efficacy and are associated with substantial toxicity. To date, key targets for molecular targeted therapy in HNSCC are epidermal growth factor receptors and angiogenesis-related factors. Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR) and it is the only targeted therapy approved by the United States Food and Drug Administration for the treatment of HNSCC. Cetuximab in combination with radiotherapy represents a standard approach for newly diagnosed patients who are unable to tolerate platinum chemotherapy. Despite efficacy in preclinical HNSCC models, cetuximab is only effective in a subset of HNSCC patients, most likely due to the high heterogeneity of this cancer. Additional targets under active investigation include the PI3K/Akt pathway, the Ras-MAPK-ERK pathway and the JAK/STAT pathway, among others. Combining molecular targeted therapies and radiation may allow for deintensification of radiotherapy thereby reducing radiation toxicities and improving treatment outcomes. Here we review the preclinical and clinical data in support of treatment strategies that combined targeted therapy with radiation in HNSCC.</div>
</front>
</TEI>
<affiliations><list><country><li>République populaire de Chine</li>
<li>États-Unis</li>
</country>
<settlement><li>Pékin</li>
</settlement>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Yu Du" sort="Yu Du" uniqKey="Yu Du" last="Yu Du">YU DU</name>
</noRegion>
<name sortKey="Grandis, Jennifer R" sort="Grandis, Jennifer R" uniqKey="Grandis J" first="Jennifer R." last="Grandis">Jennifer R. Grandis</name>
<name sortKey="Grandis, Jennifer R" sort="Grandis, Jennifer R" uniqKey="Grandis J" first="Jennifer R." last="Grandis">Jennifer R. Grandis</name>
<name sortKey="Peyser, Noah D" sort="Peyser, Noah D" uniqKey="Peyser N" first="Noah D." last="Peyser">Noah D. Peyser</name>
<name sortKey="Peyser, Noah D" sort="Peyser, Noah D" uniqKey="Peyser N" first="Noah D." last="Peyser">Noah D. Peyser</name>
</country>
<country name="République populaire de Chine"><noRegion><name sortKey="Yu Du" sort="Yu Du" uniqKey="Yu Du" last="Yu Du">YU DU</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Main/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005629 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 005629 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     Pascal:14-0117820
   |texte=   Integration of molecular targeted therapy with radiation in head and neck cancer
}}

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021

	Serveur d'exploration sur Pittsburgh
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur Pittsburgh

Integration of molecular targeted therapy with radiation in head and neck cancer

Integration of molecular targeted therapy with radiation in head and neck cancer

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri